Check two blood markers to help prevent preeclampsia
Part of Genetic & congenital, Heart & circulation, Women’s health & pregnancy clinical trials.
This trial tests whether measuring two pregnancy blood markers (sFlt1 and PlGF) and planning delivery timing can help prevent preeclampsia as you reach term. It may help reduce risk for mother and baby by guiding when to deliver based on test results.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are pregnant for the first time (no prior births).
- This is one baby only (singleton pregnancy).
- You are over 18 years old.
- You are between 35.0 and 36.6 weeks pregnant.
- You can sign the study consent form in writing.
- You are not currently in another study that could change delivery timing.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at blood-flow and artery health signs during pregnancy to better understand why preeclampsia happens. It compares women with preeclampsia to women with an uncomplicated pregnancy, and may help improve early detection and care.
This study tests whether measuring certain proteins in the blood (angiogenic factors) can help doctors better manage preeclampsia in women who are 36 to 38 weeks pregnant. The goal is to see if this approach can safely delay delivery and improve outcomes for both mother and baby.
This study looks at how early, slow fetal growth is managed during pregnancy. It compares an “angiogenic factors” approach with an ultrasound (blood-flow) approach to help guide care and improve outcomes.
This study is for pregnant women to check their risk of pre-eclampsia (a serious condition causing high blood pressure) using simple tests like blood work or ultrasound. It aims to help you and your doctor manage your pregnancy better.
This trial tests a new medicine, CBP-4888, for pregnant women hospitalized with preeclampsia starting after 20 weeks. The goal is to see if it's safe and how it works for you and your baby, who will be followed for up to 24 months after birth.
This study tests if certain blood markers can help diagnose and monitor preeclampsia. It aims to improve how this serious pregnancy condition is detected and treated.
Hear when a new Preeclampsia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.